Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study

British Journal of General Practice

Volumn 59, Issue 558, 2009, Pages 43-48

  Janssen, Paul G H ^a   Gorter, Kees J ^a   Stolk, Ronald P ^b   Rutten, Guy E H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiovascular disease; Diabetes mellitus, type 2; Primary health care; Randomised controlled trial; Screening

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GENERAL PRACTICE; HEALTH EDUCATION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FAMILY PRACTICE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; QUALITY OF LIFE; RISK FACTORS;

EID: 58149494663     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp09X394851     Document Type: Article

References (26)

1. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15(7): 815-819.
2. Rajala U, Laakso M, Qiao Q, Keinanen-Kiukaanniemi S. Prevalence of retinopathy in people with diabetes, impaired glucose tolerance and normal glucose tolerance. Diabetes Care 1998; 21(10): 1664-1669.
3. Borch-Johnsen K, Lauritzen T, Glümer C, Sandbaek A. Screening for type 2 diabetes - should it be now? Diabet Med 2003; 20(3): 175-181.
4. Colagiuri S, Cull CA, Holman RA. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UKPDS 61. Diabetes Care 2002; 25: 1410-1417.
5. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95 783 individuals followed for 12.4 years. Diabetes Care 1999; 22(2): 235-240.
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703-713.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes. Lancet 2003; 361(9374): 2005-2016.
8. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353(9153): 617-622.
9. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5): 385-393.
10. Lauritzen T, Griffin S, Borch-Johnsen K, et al. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000; 24 (Suppl 3): S6-S11.
11. Adriaanse MC, Snoek FJ, Dekker JM, et al. Screening for type 2 diabetes: an exploration of subject's perceptions regarding diagnosis and procedure. Diabet Med 2002; 19(5): 405-411.
12. Rutten GEHM, Verhoeven S, Heine RJ, et al. Dutch College of General Practitioners. Practice guideline diabetes mellitus type 2 [in Dutch]. Huis Wetensch 1999; 42: 67-84.
13. Sandbaek A, Griffin SJ, Rutten G, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008; 51(7): 1127-1134.
14. Janssen PGH, Gorter KJ, Stolk RP, Rotten GEHM. Low yield of population-based screening for Type 2 diabetes in the Netherlands: the ADDITION Netherlands study. Fam Pract 2007; 24(6): 555-661.
15. Ruige JB, de Neeling JND, Kostense PJ, et al. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 1997; 20(4): 491-496.
16. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization, 1999.
17. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473-483.
18. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32(1): 40-46.
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
20. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288(23): 2981-2997.
21. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853.
22. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560-2972.
23. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2543-2559.
24. Olivarius N de F, Beck-Nielsen H, Andreasen AH, et al. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ 2001; 323(7319): 970-975.
25. Adriaanse MC, Snoek FJ, Dekker JM, et al. No substantial psychological impact of the diagnosis of Type 2 diabetes following targeted population screening: The Hoorn Screening Study. Diabet Med 2004; 21(9): 992-998.
26. Edelman D, Olsen MK, Dudley TK, et al. Impact of diabetes screening on quality of life. Diabetes Care 2002; 25(6): 1022-1026.